868561-17-5

Basic information

• Product Name: 7-Bromo-1H-indole, N-BOC protected
• Synonyms: tert-butyl 6-broMo-1H-indole-3-carboxylate;7-Bromoindole-1-carboxylic acid tert-butyl ester;7-Bromo-1H-indole,N-BOCprotected98%;7-Bromo-1H-indole, N-BOC protected;tert-Butyl 7-bromo-1H-indole-1-carboxylate;7-Bromo-1H-indole, N-BOC protected 98%;1-BOC-7-bromoindole;t-butyl 7-bromoindole-1-carboxylate
• CAS NO: 868561-17-5
• Molecular Formula: C13H14BrNO2
• Molecular Weight: 296.15976
• Product Categories: Bromides;IndolesOxindoles;blocks
• Mol File: 868561-17-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 367.9 °C at 760 mmHg
• Flash Point: 176.3 °C
• Appearance: /
• Density: 1.37
• Vapor Pressure: 1.33E-05mmHg at 25°C
• Refractive Index: 1.576
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 7-Bromo-1H-indole, N-BOC protected(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Bromo-1H-indole, N-BOC protected(868561-17-5)
• EPA Substance Registry System: 7-Bromo-1H-indole, N-BOC protected(868561-17-5)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 868561-17-5(Hazardous Substances Data)

Usage

General Description

7-Bromo-1H-indole, N-BOC protected is a chemical compound containing a bromine atom and a N-BOC protective group attached to an indole ring. Indole is a heterocyclic aromatic organic compound that is commonly found in various natural products and pharmaceuticals. The BOC (tert-butoxycarbonyl) protective group is often used to protect amines in organic synthesis. The combination of the bromine atom and the N-BOC protective group in 7-Bromo-1H-indole, N-BOC protected makes it a valuable building block in the synthesis of complex organic molecules and pharmaceuticals. 7-Bromo-1H-indole, N-BOC protected is commonly used in the pharmaceutical and chemical industries for the production of various drugs and other organic compounds.

InChI:InChI=1/C13H14BrNO2/c1-13(2,3)17-12(16)15-8-7-9-5-4-6-10(14)11(9)15/h4-8H,1-3H3

Upstream product

• 577-19-5 2-nitrophenyl bromide 
• 51417-51-7 7-bromo-1H-indole 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 100874-07-5 7-bromo-2-phenyl-1H-indole 

Relevant articles and documents

Discovery of SY-5609: A Selective, Noncovalent Inhibitor of CDK7

CDK7 has emerged as an exciting target in oncology due to its roles in two important processes that are misregulated in cancer cells: cell cycle and transcription. This report describes the discovery of SY-5609, a highly potent (sub-nM CDK7 Kd) and selective, orally available inhibitor of CDK7 that entered the clinic in 2020 (ClinicalTrials.gov Identifier: NCT04247126). Structure-based design was leveraged to obtain high selectivity (>4000-times the closest off target) and slow off-rate binding kinetics desirable for potent cellular activity. Finally, incorporation of a phosphine oxide as an atypical hydrogen bond acceptor helped provide the required potency and metabolic stability. The development candidate SY-5609 displays potent inhibition of CDK7 in cells and demonstrates strong efficacy in mouse xenograft models when dosed as low as 2 mg/kg.

INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.

THERAPEUTIC COMPOUNDS AND USES THEREOF

The present invention relates to compounds of formula (I): and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.